Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.43 |
| ▸ | MARS1 | P56192 | 2/20 | 0.39 |
| ▸ | ACLY | P53396 | 2/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4529293 | 0.88 | ALDH1A1 (0.44) | APLNRKMT2A | |
| SCHEMBL4426073 | 0.86 | IDO1 (0.48) | FFAR4IDO1 | |
| SCHEMBL3161285 | 0.81 | FFAR4 (0.45) | FFAR4IDO1CNR1ENPP2DDR1 | |
| SCHEMBL3305248 | 0.80 | APLNR (0.37) | APLNRIDO1 | |
| SCHEMBL7465368 | 0.76 | CYP19A1 (0.41) | MEN1KMT2A | |
| SCHEMBL4209463 | 0.76 | TAS2R14 (0.45) | TP53MEN1KMT2A | |
| SCHEMBL4402201 | 0.75 | ALDH1A1 (0.44) | TP53MEN1KMT2A | |
| SCHEMBL7019854 | 0.75 | MAPT (0.44) | MEN1KMT2A | |
| SCHEMBL5103979 | 0.75 | MEN1 (0.42) | FFAR4MARS1ACLYTP53MEN1 | |
| SCHEMBL1650853 | 0.75 | MEN1 (0.39) | FFAR4MARS1ACLYMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799947-B2 | In vivo imaging compounds | HAMMERSMITH IMANET LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-7799947-B2 | In vivo imaging compounds | HAMMERSMITH IMANET LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-7799947-B2 | In vivo imaging compounds | HAMMERSMITH IMANET LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-20090155168-A1 | IN VIVO IMAGING COMPOUNDS | GE HEALTHCARE LIMITED (GB) | 2009-06-18 | — | — | US | disclosed |
| US-20090155168-A1 | IN VIVO IMAGING COMPOUNDS | GE HEALTHCARE LIMITED (GB) | 2009-06-18 | — | — | US | disclosed |
| US-20090155168-A1 | IN VIVO IMAGING COMPOUNDS | GE HEALTHCARE LIMITED (GB) | 2009-06-18 | — | — | US | disclosed |
| EP-1954259-A2 | AMIDINE DERIVATIVES FOR IN VIVO IMAGING | Hammersmith Imanet, Ltd (GB) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007063286-A2 | AMIDINE DERIVATIVES FOR IN VIVO IMAGING | HAMMERSMITH IMANET LIMITED (GB) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007063286-A2 | AMIDINE DERIVATIVES FOR IN VIVO IMAGING | HAMMERSMITH IMANET LIMITED (GB) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155168-A1 | IN VIVO IMAGING COMPOUNDS | GRIN1, GRIN2B, GRIN3B | FFAR4 313/4885MARS1 3094/4885ACLY 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.